Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Chromatin Remodeling Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BRD9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BRD9 Bromodomain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View BRD9 Products |
| Gene Delivery | BRD9 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View BRD9 Products |
| Benchmark Ab | Anti-BRD9 (Sequence of clinical benchmark) Recombinant positive control. |
View BRD9 Products |
| Validator | BRD9 siRNA Set For knockdown verification. |
View BRD9 Products |
| Related Target A | BRD7 High-homology family member; critical for off-target selectivity screening. |
View BRD7 Products |
| Related Target B | SMARCB1 Subunit of the SWI/SNF complex; synthetic lethal partner in BRD9-targeted oncology. |
View SMARCB1 Products |
| Related Target C | SMARCA4 ATPase subunit of the SWI/SNF complex; co-regulated in SWI/SNF mutant cancers. |
View SMARCA4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over BRD7 homolog | Highly purified recombinant BRD9 and BRD7 bromodomain proteins available with >95% purity and sequence verification. |
| Ternary complex formation (PROTACs) | Truncated, highly stable Bromodomain constructs optimized for biophysical assays (SPR, TR-FRET). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live BRD9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BRD9 therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted protein degraders (PROTACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the synthetic lethal relationship between BRD9 and SMARCB1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC (Targeted Degrader) | C4 Therapeutics, Foghorn Therapeutics | Synovial Sarcoma, SMARCB1-deficient tumors | Degradation kinetics assays (Need Lentivirus for reporter cell line construction) |
| Small Molecule Inhibitor | Boehringer Ingelheim | Acute Myeloid Leukemia (AML), Solid Tumors | High-throughput binding selectivity (Need BRD9 vs BRD7 recombinant proteins) |
| Molecular Glue | Monte Rosa Therapeutics | Oncology, Hematological Malignancies | Ternary complex characterization (Need sequence-verified active domains) |